rethinkMushrooms Search
Menu
Home / Microdosing
Guide

What Is Microdosing Psilocybin? A Complete Guide

Microdosing psilocybin means taking a sub-perceptual dose on a schedule. What community surveys report and what blinded controlled trials show are two different things.

RethinkMushrooms Research TeamUpdated 15 min read

Microdosing

191 participants

A 2021 self-blinding RCT found that after successful blinding, no statistically significant differences appeared between active microdose and placebo groups — suggesting expectancy drives much of what microdosers report.

Szigeti et al., eLife, 2021

0.1-0.3g

typical dried Psilocybe cubensis microdose range used in community surveys (Anderson, 2019)

3 RCTs

found no creativity benefit versus placebo (Prochazkova et al., 2026)

Schedule I

federal legal status of psilocybin in the United States — illegal for personal use in most states

Szigeti et al., eLife, 2021

Microdosing psilocybin evidence overview: survey data vs. controlled trial findingsView as image ↗

Microdosing psilocybin means taking a dose of psilocybin — the compound in "magic mushrooms" — small enough to avoid psychoactive effects while potentially affecting mood, focus, or cognition. Typical doses in the research literature range from 0.1 to 0.3 grams of dried Psilocybe cubensis mushroom (or 1 to 3 milligrams of purified psilocybin), taken on a schedule with rest days. The goal is sub-perceptual: no visual changes, no perceptual distortion, functional daily life.

Psilocybin is a Schedule I controlled substance in the United States, making personal use federally illegal regardless of intent or dose. Oregon and Colorado have created limited frameworks for regulated therapeutic use; personal microdosing remains illegal under federal law and in most states.

This guide covers what microdosing is, what the evidence from surveys and controlled trials shows, what the proposed mechanisms are, and what the known safety concerns are. The evidence is uneven — and being honest about that unevenness is the only way to give this topic the treatment it deserves.

Key Takeaways

  • Microdosing means taking 0.1-0.3g of dried Psilocybe cubensis (or 1-3mg synthetic psilocybin) on a schedule — a dose intended to be sub-perceptual and non-impairing
  • Community surveys of thousands of microdosers report improvements in mood, focus, and creativity — but these are self-selected populations without placebo controls
  • A 2021 self-blinding RCT of 191 participants found no statistically significant differences between active and placebo groups after successful blinding, suggesting expectancy drives much of what people report (Szigeti et al., eLife, 2021)
  • Three separate double-blind placebo-controlled longitudinal RCTs found no creativity benefit compared to placebo — directly challenging the most commonly claimed benefit of microdosing (Prochazkova et al., 2026)
  • A 2024 analysis quantified cardiac risk: even at microdosing levels, psilocybin activates 5-HT2B receptors, which are associated with valvulopathy from other drugs. Daily long-term use is the primary risk scenario (Rouaud, Calder & Hasler, 2024)
  • Psilocybin is Schedule I federally in the US; most controlled trial evidence comes from jurisdictions where research exemptions exist

What Microdosing Means: The Sub-Perceptual Standard

Microdosing psilocybin means taking a sub-perceptual dose of psilocybin on a schedule, with the intention of improving mood, focus, or creativity without experiencing psychoactive effects. A properly calibrated microdose produces no visual alterations, no significant perceptual change, and no impairment of daily function.

The most common dose range cited in community surveys: 0.1 to 0.3 grams of dried Psilocybe cubensis, the most widely available psilocybin-containing mushroom species.[1] Research settings typically use 1 to 3 milligrams of purified psilocybin. These ranges are not directly comparable because the psilocybin content of dried mushrooms varies substantially by strain, growing conditions, and storage.

Most protocols involve a schedule with rest days rather than daily use. The two most common community protocols are the Fadiman protocol (1 day on, 2 days off) and the Stamets Stack (5 days on, 2 days off). Neither has been compared against the other in a controlled trial.

The purpose of rest days is to avoid tolerance buildup and habituation. Whether tolerance develops at these doses, how quickly, and whether it affects benefits, is not well-characterized in controlled research.

Where Microdosing Started: Fadiman, Surveys, and What They Show

The academic articulation of modern microdosing practices begins with James Fadiman, a psychologist who collected self-reports from microdosers and published preliminary findings in 2019 with Sophia Korb.[2] Their paper described Fadiman's 1-day-on, 2-days-off schedule and reported self-described improvements in mood, productivity, and creativity. There was no control group. All data was self-reported by people who had sought out Fadiman's work and adopted the practice.

A 2019 survey study by Anderson and colleagues gathered self-reported data from 278 people who had experience with microdosing.[1] The most commonly reported benefits: improved focus (26% of respondents), better mood (25%), and enhanced creativity (25%). The most commonly reported challenges: anxiety (18%), impaired focus at doses that were too high (9%), and physiological discomfort (9%). The Fadiman protocol was the most used schedule, reported by 38% of respondents.

These surveys describe what microdosers believe is happening to them. They do not tell us whether psilocybin is causing those effects or whether other factors — belief, expectation, changing habits during a protocol — are responsible.

The Most-Cited Positive Study: 8,703 Participants and One Undisclosed Conflict

In 2021, Rootman and colleagues published a naturalistic cohort study in Scientific Reports that enrolled 8,703 participants, comparing self-reported mental health outcomes between microdosers and non-microdosers.[3] The results: microdosers reported significantly lower depression (Cohen's d = -0.36) and anxiety (d = -0.30) compared to non-microdosers, along with higher wellbeing scores.

This is the most-cited positive microdosing study and it is cited extensively by advocacy sites, microdosing programs, and supplement companies.

What those sites do not typically disclose: Paul Stamets — the patent holder of the Stamets Stack combination — is a co-author on this paper. Stamets has a direct financial interest in the commercialization of psilocybin microdosing protocols. The study is also entirely naturalistic: people who chose to microdose, believed it was helping them, and enrolled in a study about it. People who stopped because it made them feel worse were less likely to be represented. These are not criticisms that make the findings meaningless. They are reasons to interpret the magnitude of the effects cautiously.

The Controlled Evidence: What Happens When You Blind the Study

The key methodological challenge in microdosing research is blinding. Participants who have consumed psilocybin often know they have, even at sub-perceptual doses, because of subtle effects they can detect. When participants know they are on active drug, their expectations shape their reports.

In 2021, Szigeti and colleagues ran a citizen science study to address this directly.[4] They enrolled 191 participants who self-prepared blinded capsules (some active, some placebo) and tested whether they could identify which was which. Among participants who could not correctly guess their condition (those who were successfully blinded), the study found no statistically significant differences between active microdose and placebo groups on primary outcomes. People who believed they were on active drug showed improvements — but when that belief was removed, the group-level difference disappeared.

A 2022 double-blind placebo-controlled RCT by Cavanna and colleagues provided an important partial counterpoint.[5] They found that active microdoses produced detectable neurophysiological changes on EEG — measurable brain activity differences that distinguished active from placebo. Psilocybin microdoses do reach the brain and do something. What Cavanna found, however, is that these measurable brain changes did not translate clearly into differentiated subjective psychological benefits at the group level.

A 2024 rapid review by Polito and Liknaitzky synthesized the controlled trial literature and reached a direct conclusion: most controlled microdosing studies fail to find specific pharmacological effects beyond expectancy.[7] The authors do not conclude that microdosing has no effect. They conclude that expectancy — the belief that one is taking an active substance — is a primary driver of reported benefits in unblinded studies. Separating pharmacological effect from expectancy requires blinded designs that are technically difficult to run.

A 2024 comprehensive review by Savides and Outhoff summarized the field: naturalistic studies consistently show positive effects; controlled studies show smaller effects with higher methodological quality; the main conclusion is evidence promising but mixed.[9]

For a deeper look at the placebo question in controlled research, see Is Microdosing Just Placebo? The Self-Blinding Studies.

The Creativity Claim: Three RCTs, Zero Benefit

Creativity is the most frequently cited claimed benefit of microdosing — cited by 25% of the Anderson 2019 survey respondents, and prominent in almost all community and commercial content about microdosing. In 2026, Prochazkova and colleagues published findings from three separate double-blind, placebo-controlled, longitudinal randomized controlled trials examining whether microdosing improved creativity.[13]

None of the three RCTs found significant creativity benefits compared to placebo.

The authors concluded that the creativity narrative is driven by open-label expectancy — the same mechanism Szigeti 2021 identified more broadly. When participants know they are taking psilocybin, they report improved creativity. When successfully blinded, the effect disappears at the group level.

A 2026 meta-analysis by Pinhas and colleagues on cognitive effects more broadly found some evidence of improved cognitive flexibility with microdosing, but no reliable improvement in convergent thinking (the kind of problem-solving that would show up on standard creativity measures).[12] No cognitive impairment was found at sub-perceptual doses. The cognitive picture is: not harmful at these doses, inconsistently beneficial.

For the full creativity research review, see Microdosing and Creativity: What the Research Shows.

The Proposed Mechanism: Why Psilocybin Might Work at Sub-Perceptual Doses

Psilocybin's primary mechanism is 5-HT2A receptor agonism. Psilocin (the active metabolite after ingestion) binds to serotonin receptors in the prefrontal cortex, triggering a cascade that includes increased BDNF (brain-derived neurotrophic factor) expression, dendritic spine growth, and reduced neuroinflammatory markers.

A 2025 review by Kinderlehrer covers these mechanisms in detail and explains the theoretical basis for the Stamets Stack's neuroplasticity hypothesis.[10] The honest caveat: most of the mechanistic research uses full doses, not microdoses. Whether microdoses trigger the same BDNF increases and structural changes is extrapolated from the higher-dose literature, not confirmed at microdose levels in humans.

The Cavanna 2022 EEG finding is relevant here: sub-perceptual doses do produce measurable central nervous system changes. The brain is responding. Whether those responses are at the right magnitude to produce therapeutic-level neuroplastic changes remains an open question.

The Safety Picture: The Cardiac Concern That Gets Buried

Most microdosing guides spend two sentences on safety before moving on. The cardiac concern warrants more careful treatment.

Psilocybin activates not only 5-HT2A receptors (the target for psychedelic effects) but also 5-HT2B receptors, which are found on cardiac valve tissue. Chronic 5-HT2B receptor activation is associated with cardiac valvulopathy — scarring of heart valves — a drug side effect seen with fenfluramine (the "fen" in fen-phen) and with ergot-derived compounds at similar receptor occupancy levels.

A 2024 analysis by Rouaud, Calder, and Hasler quantified this risk specifically for microdosing.[8] Even at doses 100 times below recreational levels, psilocybin can activate 5-HT2B receptors with chronic daily use. The receptor occupancy at daily microdosing doses reaches levels comparable to drugs known to cause valvulopathy. No confirmed cases of microdosing-induced valvulopathy exist in the published literature. But daily, long-term use — rather than the schedule-with-rest-days approach — is the scenario that most closely resembles the risk profile of problematic 5-HT2B-activating drugs.

A 2025 review in Nature Cardiovascular Research by Nahlawi, Ptaszek, and Ruskin confirmed that acute hemodynamic effects of psilocybin (blood pressure and heart rate increases) are mild and transient, but that chronic 5-HT2B concern is the primary theoretical long-term cardiac risk.[11] The authors recommend cardiac monitoring for anyone microdosing daily for extended periods.

A 2023 review by Wsół reached the same theoretical concern conclusion and noted that the safety data specifically for long-term microdosing protocols is absent — most trial data covers acute or short-term use.[6]

The practical implication: the protocols that include scheduled rest days (Fadiman's 1-on-2-off, for example) may carry lower cardiac risk than daily dosing, because intermittent 5-HT2B activation is less likely to produce cumulative valvular changes. This is theoretical — no comparison data exists — but it is consistent with what is known about the dose-duration relationship for 5-HT2B valvulopathy.

For a detailed breakdown of the 5-HT2B concern, see Microdosing and Heart Health: The 5-HT2B Valvulopathy Concern.

Protocols: Fadiman, Stamets, and What the Research Does and Doesn't Compare

The two most discussed community protocols are:

The Fadiman protocol: 1 day of microdosing, followed by 2 days off. Designed to allow effects to dissipate and avoid tolerance. First described in academic literature in Fadiman & Korb 2019.[2] The most commonly used schedule in community surveys, adopted by 38% of Anderson 2019 respondents.[1]

The Stamets Stack: 5 days of microdosing, followed by 2 days off. Combines psilocybin with lion's mane mushroom and niacin. Described in a US patent (US20180021326A1) filed by Paul Stamets in 2019. The combination has never been tested in a peer-reviewed clinical trial. The neuroplasticity rationale (lion's mane + psilocybin for synergistic BDNF/NGF support) is theoretically coherent but unverified as a combination.

No head-to-head comparison between these protocols has been conducted in a controlled trial. Savides 2024 explicitly notes this gap.[9]

For a full protocol comparison, see Microdosing Protocols Compared: Fadiman vs. Stamets vs. Every Other Day. For the Fadiman protocol in depth, see The Fadiman Protocol: The Original Microdosing Schedule. For the Stamets Stack, see The Stamets Stack: Lion's Mane, Niacin, and Psilocybin.

Psilocybin is classified as a Schedule I controlled substance under the Controlled Substances Act. Schedule I means: no accepted medical use (at the federal level), high potential for abuse, and no legally authorized personal use outside specific research exemptions.

This classification is why microdosing research is thin. Conducting controlled trials requires DEA Schedule I researcher licenses, specialized facilities, and IRB approval processes that most academic institutions find prohibitively complex. The best-powered naturalistic studies are conducted online precisely because in-person research is legally constrained.

Oregon passed Measure 109 in 2020, creating a regulated therapeutic psilocybin framework that launched in 2023. Colorado passed Proposition 122 in 2022, allowing supervised use in licensed healing centers. In both states, personal microdosing outside these frameworks remains illegal.

The legal status also constrains how much can be said publicly about microdosing by clinicians, researchers, and companies — which is part of why the community evidence base is built on surveys rather than registrational trials.

The Bottom Line

Microdosing psilocybin involves taking sub-perceptual doses on a schedule with rest days. Community surveys consistently report benefits in mood, focus, and creativity, but these are unblinded, self-selected populations. Controlled trials — especially Szigeti 2021 and the Prochazkova 2026 three-RCT creativity study — find smaller effects with larger placebo contributions. Expectancy appears to be a major driver of reported benefits. A theoretical cardiac concern exists from chronic 5-HT2B receptor activation at daily microdosing levels. Psilocybin remains Schedule I federally in the US, making personal microdosing illegal in most jurisdictions.

Frequently Asked Questions

Sources & References

  1. 1RTHM-00541·Anderson, Thomas et al. (2019). “Psychedelic microdosing benefits and challenges: an empirical codebook..” Harm reduction journal.Study breakdown →PubMed →↩
  2. 2RTHM-01054·Fadiman, James et al. (2019). “Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration..” Journal of psychoactive drugs.Study breakdown →PubMed →↩
  3. 3RTHM-00715·Rootman, Joseph M et al. (2021). “Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers..” Scientific reports.Study breakdown →PubMed →↩
  4. 4RTHM-01441·Szigeti, Balázs et al. (2021). “Self-blinding citizen science to explore psychedelic microdosing..” eLife.Study breakdown →PubMed →↩
  5. 5RTHM-00748·Cavanna, Federico et al. (2022). “Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study..” Translational psychiatry.Study breakdown →PubMed →↩
  6. 6RTHM-01822·Wsół, Agnieszka (2023). “Cardiovascular safety of psychedelic medicine: current status and future directions..” Pharmacological reports : PR.Study breakdown →PubMed →↩
  7. 7RTHM-00900·Polito, Vince et al. (2024). “Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
  8. 8RTHM-00903·Rouaud, Antonin et al. (2024). “Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
  9. 9RTHM-00905·Savides, Isabella A et al. (2024). “Less is more? A review of psilocybin microdosing..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
  10. 10RTHM-00929·Kinderlehrer, Daniel A (2025). “Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity..” Neuropsychiatric disease and treatment.Study breakdown →PubMed →↩
  11. 11RTHM-02156·Nahlawi, Acile et al. (2025). “Cardiovascular effects and safety of classic psychedelics..” Nature cardiovascular research.Study breakdown →PubMed →↩
  12. 12RTHM-00961·Pinhas, Netta et al. (2026). “Effects of psychedelic microdosing on cognitive functions: A systematic review and meta-analysis..” Neuroscience and biobehavioral reviews.Study breakdown →PubMed →↩
  13. 13RTHM-00962·Prochazkova, Luisa et al. (2026). “Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials..” Neuropharmacology.Study breakdown →PubMed →↩